• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characteristics and Outcomes of Children and Adolescents With Epithelial Ovarian Neoplasms From a Tertiary Cancer Centre in Western India: A Retrospective Study.印度西部一家三级癌症中心上皮性卵巢肿瘤儿童和青少年的特征及结局:一项回顾性研究
Cureus. 2025 May 22;17(5):e84650. doi: 10.7759/cureus.84650. eCollection 2025 May.
2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤(使用RobotReviewer软件进行的快速综述)
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.
4
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
5
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化:个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
7
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.超根治性(广泛)手术与标准手术治疗晚期上皮性卵巢癌的初步细胞减灭术。
Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3.
8
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.根治性子宫切除术联合放化疗与单纯根治性子宫切除术治疗局部晚期宫颈癌的疗效比较
Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD010260. doi: 10.1002/14651858.CD010260.pub3.
9
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
10
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.聚(ADP-核糖)聚合酶(PARP)抑制剂治疗卵巢癌。
Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.

本文引用的文献

1
First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.奥拉帕利治疗耐药性实体瘤儿科患者的首次 1 期临床研究。
Cancer. 2022 Aug 1;128(15):2949-2957. doi: 10.1002/cncr.34270. Epub 2022 May 20.
2
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.卵巢、输卵管及腹膜癌:2021年更新
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):61-85. doi: 10.1002/ijgo.13878.
3
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
4
Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.新辅助化疗在晚期上皮性卵巢癌中的作用
J Clin Oncol. 2019 Sep 20;37(27):2398-2405. doi: 10.1200/JCO.19.00022. Epub 2019 Aug 12.
5
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.奥拉帕利维持治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
6
Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.儿科和青少年人群中的恶性及交界性上皮性卵巢肿瘤。
Maturitas. 2017 Feb;96:45-50. doi: 10.1016/j.maturitas.2016.11.011. Epub 2016 Nov 15.
7
Ovarian cancer in children and adolescents: A rare disease that needs more attention.儿童和青少年卵巢癌:一种需要更多关注的罕见疾病。
Maturitas. 2016 Jun;88:3-8. doi: 10.1016/j.maturitas.2016.03.003. Epub 2016 Mar 8.
8
Epithelial Tumors of the Ovary in Children and Teenagers: A Prospective Study from the Italian TREP Project.儿童和青少年卵巢上皮性肿瘤:来自意大利TREP项目的前瞻性研究
J Pediatr Adolesc Gynecol. 2015 Dec;28(6):441-6. doi: 10.1016/j.jpag.2014.12.010. Epub 2014 Dec 29.
9
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.新诊断卵巢癌女性使用或不使用贝伐单抗的标准化疗(ICON7):一项3期随机试验的总生存结果
Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.
10
Ovarian surface epithelial neoplasms in the pediatric population: incidence, histologic subtype, and natural history.儿童人群中的卵巢表面上皮性肿瘤:发病率、组织学亚型和自然病史。
Am J Surg Pathol. 2013 Apr;37(4):548-53. doi: 10.1097/PAS.0b013e318273a9ff.

印度西部一家三级癌症中心上皮性卵巢肿瘤儿童和青少年的特征及结局:一项回顾性研究

Characteristics and Outcomes of Children and Adolescents With Epithelial Ovarian Neoplasms From a Tertiary Cancer Centre in Western India: A Retrospective Study.

作者信息

Trivedi Maharshi, Meena Pinky, Tak Himangi, Dave Dipesh, Chandra Minu, Joshi Nitin, Panchal Harsha P, Gandhi Jahnavi

机构信息

Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, IND.

Pediatrics, All India Institute of Medical Sciences, Rajkot, IND.

出版信息

Cureus. 2025 May 22;17(5):e84650. doi: 10.7759/cureus.84650. eCollection 2025 May.

DOI:10.7759/cureus.84650
PMID:40546506
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12182444/
Abstract

Epithelial ovarian neoplasms (EON) are uncommon in children and data is limited. We conducted this study to assess the clinical characteristics and outcomes of children and adolescents with EON. Children ≤18 years of age diagnosed with EON, between 1st January 2010 and 31st December 2022 were included for retrospective analysis. Clinical characteristics, treatment details, and outcomes were noted. One-hundred-sixteen patients were diagnosed with ovarian mass, and eight (0.07%) of them were EON. Median age was 17 years (range: 13-18 years). One (12.5%) patient had a family history of breast cancer. One (12.5%) had borderline serous cystadenocarcinoma, four (50%) had malignant serous, and three (37.5%) had malignant mucinous adenocarcinoma. One girl with borderline disease (stage Ia) was treated with surgery and is alive. Among seven patients with malignant EONs, two (28.6%), two (28.6%), two (28.6%), and one (14.2%) had stage Ia, II, IIIc, and Iva disease, respectively. Two (28.6%) patients underwent primary debulking surgery. Two patients (28.6%) received neoadjuvant chemotherapy (NACT) followed by interval debulking. Three (42.8%) patients received chemotherapy and did not undergo surgery because of stable/progressive disease. Two patients (25%) with stage Ia were alive without evidence of disease. One girl (12.5%) with stage IIb relapsed after primary treatment and succumbed to the disease. All three patients with stage IIIc and one with stage IVa had relapse/progression, and three patients succumbed to the disease. Malignant EONs require multimodality treatment. Advanced disease and serous tumors are associated with poor survival. With a mean (± standard deviation) follow-up of 56 ± 10 months, the three-year progression-free survival (PFS) and overall survival (OS) were 37.5%±17.1% and 70%±18.2%, respectively.

摘要

上皮性卵巢肿瘤(EON)在儿童中并不常见,相关数据有限。我们开展这项研究以评估患有EON的儿童和青少年的临床特征及预后情况。纳入2010年1月1日至2022年12月31日期间诊断为EON的18岁及以下儿童进行回顾性分析。记录临床特征、治疗细节及预后情况。116例患者被诊断为卵巢肿块,其中8例(0.07%)为EON。中位年龄为17岁(范围:13 - 18岁)。1例(12.5%)患者有乳腺癌家族史。1例(12.5%)患有交界性浆液性囊腺癌,4例(50%)患有恶性浆液性肿瘤,3例(37.5%)患有恶性黏液性腺癌。1例患有交界性疾病(Ia期)的女孩接受手术治疗后存活。在7例恶性EON患者中,分别有2例(28.6%)、2例(28.6%)、2例(28.6%)和1例(14.2%)患有Ia期、II期、IIIc期和IVa期疾病。2例(28.6%)患者接受了初次肿瘤细胞减灭术。2例患者(28.6%)接受了新辅助化疗(NACT),随后进行间隔性肿瘤细胞减灭术。3例(42.8%)患者接受化疗,因疾病稳定/进展未接受手术。2例Ia期患者(25%)存活且无疾病证据。1例IIb期女孩(12.5%)在初次治疗后复发并死于该疾病。所有3例IIIc期患者和1例IVa期患者均出现复发/进展,3例患者死于该疾病。恶性EON需要多模式治疗。晚期疾病和浆液性肿瘤与较差的生存率相关。平均(±标准差)随访56±10个月,三年无进展生存率(PFS)和总生存率(OS)分别为37.5%±17.1%和70%±18.2%。